Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
Fiche publication
Date publication
janvier 2019
Journal
Current medicinal chemistry
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Martelli L, Peyrin-Biroulet L
Lien Pubmed
Résumé
Anti-tumor necrosis factor (anti-TNF) monoclonal antibodies have revolutionized the treatment of inflammatory bowel diseases (IBD). However, because of their complexity, their production is expensive contributing to their high price. As the patent protection of these therapies has expired in several countries, biosimilars have been developed to reduce the healthcare costs. The aim of this article is to review the literature on the safety, efficacy and immunogenicity of biosimilars in IBD.
Mots clés
Biosimilar, CT-P13, efficacy, immunogenicity, inflammatory bowel disease, infliximab, safety.
Référence
Curr. Med. Chem.. 2019 ;26(2):270-279